301393 昊帆生物
已收盘 08-16 15:00:00
资讯
新帖
简况
昊帆生物(301393)8月2日主力资金净买入731.24万元
证券之星 · 08-05
昊帆生物(301393)8月2日主力资金净买入731.24万元
昊帆生物(301393.SZ)向125名激励对象授予71.6万股限制性股票
智通财经 · 07-26
昊帆生物(301393.SZ)向125名激励对象授予71.6万股限制性股票
昊帆生物(301393.SZ)部分董事高管合计完成增持38.03万股
智通财经 · 07-22
昊帆生物(301393.SZ)部分董事高管合计完成增持38.03万股
民生证券保荐昊帆生物IPO项目质量评级D级 新股弃购率高达5.30% 发行市盈率高于行业均值271.15%
新浪证券 · 07-20
民生证券保荐昊帆生物IPO项目质量评级D级 新股弃购率高达5.30% 发行市盈率高于行业均值271.15%
昊帆生物:7月18日高管吕敏杰增持股份合计1.57万股
证券之星 · 07-19
昊帆生物:7月18日高管吕敏杰增持股份合计1.57万股
昊帆生物:7月17日高管徐杰、陆雪根、吕敏杰、董胜军增持股份合计7.77万股
证券之星 · 07-18
昊帆生物:7月17日高管徐杰、陆雪根、吕敏杰、董胜军增持股份合计7.77万股
昊帆生物:7月16日高管徐杰、陆雪根、董胜军增持股份合计5.99万股
证券之星 · 07-17
昊帆生物:7月16日高管徐杰、陆雪根、董胜军增持股份合计5.99万股
昊帆生物(301393)1651.45万股限售股将于7月15日解禁,占总股本15.29%
证券之星 · 07-15
昊帆生物(301393)1651.45万股限售股将于7月15日解禁,占总股本15.29%
昊帆生物:7月11日高管陆雪根增持股份合计1000股
证券之星 · 07-12
昊帆生物:7月11日高管陆雪根增持股份合计1000股
昊帆生物:7月10日高管徐杰、董胜军增持股份合计6.85万股
证券之星 · 07-11
昊帆生物:7月10日高管徐杰、董胜军增持股份合计6.85万股
昊帆生物:7月8日高管董胜军、吕敏杰增持股份合计10.71万股
证券之星 · 07-09
昊帆生物:7月8日高管董胜军、吕敏杰增持股份合计10.71万股
昊帆生物(301393)7月4日主力资金净买入735.43万元
证券之星 · 07-05
昊帆生物(301393)7月4日主力资金净买入735.43万元
昊帆生物:7月4日高管徐杰、陆雪根、吕敏杰、董胜军增持股份合计2.54万股
证券之星 · 07-04
昊帆生物:7月4日高管徐杰、陆雪根、吕敏杰、董胜军增持股份合计2.54万股
昊帆生物(301393.SZ)获多位董高合计增持2.54万股
智通财经网 · 07-04
昊帆生物(301393.SZ)获多位董高合计增持2.54万股
昊帆生物最新公告:部分董事、高管拟1100万元-2200万元增持股份
证券之星 · 07-04
昊帆生物最新公告:部分董事、高管拟1100万元-2200万元增持股份
昊帆生物涨5.52%,开源证券二个月前给出“买入”评级
证券之星 · 06-24
昊帆生物涨5.52%,开源证券二个月前给出“买入”评级
昊帆生物(301393.SZ)拟投建多肽合成试剂生产项目(一期) 投资总额10亿元
智通财经 · 06-21
昊帆生物(301393.SZ)拟投建多肽合成试剂生产项目(一期) 投资总额10亿元
昊帆生物(301393.SZ)拟推2024年限制性股票激励计划
智通财经 · 06-21
昊帆生物(301393.SZ)拟推2024年限制性股票激励计划
昊帆生物最新公告:拟10亿元投建多肽合成试剂生产项目
证券之星 · 06-21
昊帆生物最新公告:拟10亿元投建多肽合成试剂生产项目
昊帆生物(301393)6月20日主力资金净买入1642.22万元
证券之星 · 06-21
昊帆生物(301393)6月20日主力资金净买入1642.22万元
公司概况
公司名称:
苏州昊帆生物股份有限公司
所属行业:
化学原料和化学制品制造业
上市日期:
2023-07-12
主营业务:
苏州昊帆生物股份有限公司主营业务为多肽合成试剂的研发、生产与销售。主要产品包括缩合试剂、保护试剂、手性消旋抑制试剂、蛋白质交联剂、蛋白质还原剂、通用型分子砌块、脂质体与脂质纳米粒药用试剂等。公司可为下游客户提供近150种结构新颖、质量优异的多肽合成试剂产品,是全球为数不多的能够提供全系列多肽合成试剂研发与产业化的公司之一,并在HATU、HBTU、TBTU、PyBOP等多个合成工艺更为先进、产品附加值更高、竞争壁垒更高的磷正离子型和脲正离子型产品领域处于市场主导地位。
发行价格:
67.68
{"stockData":{"symbol":"301393","market":"SZ","secType":"STK","nameCN":"昊帆生物","latestPrice":39.08,"timestamp":1723791801000,"preClose":38.2,"halted":0,"volume":963300,"delay":0,"floatShares":35653000,"shares":108000000,"eps":0.8567,"marketStatus":"已收盘","marketStatusCode":5,"change":0.88,"latestTime":"08-16 15:00:00","open":38,"high":39.17,"low":37.8,"amount":37273000,"amplitude":0.0359,"askPrice":39.08,"askSize":12,"bidPrice":39.06,"bidSize":3,"shortable":0,"etf":0,"ttmEps":0.8567,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724031000000},"adr":0,"adjPreClose":38.2,"symbolType":"stock","openAndCloseTimeList":[[1723771800000,1723779000000],[1723784400000,1723791600000]],"highLimit":42.02,"lowLimit":34.38,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":108000000,"pbRate":1.85,"roa":"--","roe":"1.34%","epsLYR":1.07,"committee":-0.436709,"marketValue":4221000000,"floatMarketCap":1393000000,"peRate":45.616902,"changeRate":0.023,"turnoverRate":0.027,"status":0},"requestUrl":"/m/hq/s/301393/wiki","defaultTab":"wiki","newsList":[{"id":"2457769576","title":"昊帆生物(301393)8月2日主力资金净买入731.24万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457769576","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457769576?lang=zh_cn&edition=full","pubTime":"2024-08-05 09:12","pubTimestamp":1722820328,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月2日收盘,昊帆生物报收于41.97元,上涨4.51%,换手率7.8%,成交量2.78万手,成交额1.17亿元。近5日资金流向一览见下表:昊帆生物融资融券信息显示,融资方面,当日融资买入797.71万元,融资偿还526.09万元,融资净买入271.62万元。昊帆生物主营业务:多肽合成试剂、通用型分子砌块及蛋白质试剂等产品的研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080500002521.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2454312175","title":"昊帆生物(301393.SZ)向125名激励对象授予71.6万股限制性股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2454312175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454312175?lang=zh_cn&edition=full","pubTime":"2024-07-26 18:50","pubTimestamp":1721991053,"startTime":"0","endTime":"0","summary":"智通财经APP讯,昊帆生物(301393.SZ)发布公告,公司审议通过了《关于向激励对象首次授予限制性股票的议案》,确定2024年7月26日为首次授予日,以22.30元/股的价格向符合条件的125名激励对象授予71.6万股第二类限制性股票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1156243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2453758923","title":"昊帆生物(301393.SZ)部分董事高管合计完成增持38.03万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2453758923","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453758923?lang=zh_cn&edition=full","pubTime":"2024-07-22 15:52","pubTimestamp":1721634772,"startTime":"0","endTime":"0","summary":"智通财经APP讯,昊帆生物(301393.SZ)发布公告,公司部分董事、高级管理人员已通过深圳证券交易所证券交易系统以集中竞价方式合计增持公司股份38.03万股,占公司总股本的比例为0.35%,合计已增持金额1522.42万元,达到增持计划金额下限,本次增持计划实施完毕。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2452026057","title":"民生证券保荐昊帆生物IPO项目质量评级D级 新股弃购率高达5.30% 发行市盈率高于行业均值271.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452026057","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452026057?lang=zh_cn&edition=full","pubTime":"2024-07-20 22:28","pubTimestamp":1721485680,"startTime":"0","endTime":"0","summary":" 报告期内,发行人及其子公司共受到1项行政处罚。 昊帆生物的承销及保荐费用为14618.88万元,承销保荐佣金率为8.00%,高于整体平均数6.35%,高于保荐人民生证券2023年度IPO承销项目平均佣金率7.97%。 上市三个月股价较发行价格上涨28.95%。 昊帆生物的发行市盈率为57.38倍,行业均数15.46倍,公司高于行业均值271.15%。 昊帆生物IPO项目总得分为67.5分,分类D级。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/observe/2024-07-20/doc-incevaiv6510050.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2024-07-20/doc-incevaiv6510050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["161027","301393"],"gpt_icon":0},{"id":"2452475878","title":"昊帆生物:7月18日高管吕敏杰增持股份合计1.57万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452475878","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452475878?lang=zh_cn&edition=full","pubTime":"2024-07-19 21:01","pubTimestamp":1721394117,"startTime":"0","endTime":"0","summary":"证券之星消息,根据7月19日市场公开信息、上市公司公告及交易所披露数据整理,昊帆生物最新董监高及相关人员股份变动情况:2024年7月18日公司董事,高管吕敏杰共增持公司股份1.57万股,占公司总股本为0.0145%。昊帆生物近半年内的董监高及核心技术人员增减持详情如下:昊帆生物的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流出353.9万,融资余额减少;融券净流出500.0,融券余额减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071900050173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2452489109","title":"昊帆生物:7月17日高管徐杰、陆雪根、吕敏杰、董胜军增持股份合计7.77万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452489109","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452489109?lang=zh_cn&edition=full","pubTime":"2024-07-18 21:01","pubTimestamp":1721307711,"startTime":"0","endTime":"0","summary":"证券之星消息,根据7月18日市场公开信息、上市公司公告及交易所披露数据整理,昊帆生物最新董监高及相关人员股份变动情况:2024年7月17日公司董事,高管徐杰、董事,高管陆雪根、董事,高管吕敏杰、董秘,高管董胜军共增持公司股份7.77万股,占公司总股本为0.072%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071800043908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2452151472","title":"昊帆生物:7月16日高管徐杰、陆雪根、董胜军增持股份合计5.99万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452151472","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452151472?lang=zh_cn&edition=full","pubTime":"2024-07-17 21:01","pubTimestamp":1721221294,"startTime":"0","endTime":"0","summary":"证券之星消息,根据7月17日市场公开信息、上市公司公告及交易所披露数据整理,昊帆生物最新董监高及相关人员股份变动情况:2024年7月16日公司董事,高管徐杰、董事,高管陆雪根、董秘,高管董胜军共增持公司股份5.99万股,占公司总股本为0.0555%。昊帆生物近半年内的董监高及核心技术人员增减持详情如下:昊帆生物的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流出113.13万,融资余额减少;融券净流出900.0,融券余额减少。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071700043206.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2451317654","title":"昊帆生物(301393)1651.45万股限售股将于7月15日解禁,占总股本15.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2451317654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451317654?lang=zh_cn&edition=full","pubTime":"2024-07-15 08:03","pubTimestamp":1721001794,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,昊帆生物于7月15日将有1651.45万股限售股份解禁,为公司首发原股东限售股份,首发战略配售股份,占公司总股本15.29%。最近一年内,该股累计解禁133.28万股,占总股本的1.23%。本次解禁后,公司还有7234.7万股限售股份,占总股本66.99%。昊帆生物主营业务:多肽合成试剂、通用型分子砌块及蛋白质试剂等产品的研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071500001515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2450580011","title":"昊帆生物:7月11日高管陆雪根增持股份合计1000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450580011","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450580011?lang=zh_cn&edition=full","pubTime":"2024-07-12 21:01","pubTimestamp":1720789278,"startTime":"0","endTime":"0","summary":"证券之星消息,根据7月12日市场公开信息、上市公司公告及交易所披露数据整理,昊帆生物最新董监高及相关人员股份变动情况:2024年7月11日公司董事,高管陆雪根共增持公司股份1000.0股,占公司总股本为0.0009%。昊帆生物近半年内的董监高及核心技术人员增减持详情如下:昊帆生物的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流出518.37万,融资余额减少;融券净流出500.0,融券余额减少。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071200050504.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2450535769","title":"昊帆生物:7月10日高管徐杰、董胜军增持股份合计6.85万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450535769","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450535769?lang=zh_cn&edition=full","pubTime":"2024-07-11 21:01","pubTimestamp":1720702888,"startTime":"0","endTime":"0","summary":"证券之星消息,根据7月11日市场公开信息、上市公司公告及交易所披露数据整理,昊帆生物最新董监高及相关人员股份变动情况:2024年7月10日公司董事,高管徐杰、董秘,高管董胜军共增持公司股份6.85万股,占公司总股本为0.0634%。昊帆生物近半年内的董监高及核心技术人员增减持详情如下:昊帆生物的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流出514.13万,融资余额减少;融券净流入1600.0,融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071100041282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2450042134","title":"昊帆生物:7月8日高管董胜军、吕敏杰增持股份合计10.71万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450042134","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450042134?lang=zh_cn&edition=full","pubTime":"2024-07-09 21:01","pubTimestamp":1720530092,"startTime":"0","endTime":"0","summary":"证券之星消息,根据7月9日市场公开信息、上市公司公告及交易所披露数据整理,昊帆生物最新董监高及相关人员股份变动情况:2024年7月8日公司董秘,高管董胜军、董事,高管吕敏杰共增持公司股份10.71万股,占公司总股本为0.0992%。昊帆生物近半年内的董监高及核心技术人员增减持详情如下:昊帆生物的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流出872.22万,融资余额减少;融券净流出100.0,融券余额减少。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070900047709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2449640401","title":"昊帆生物(301393)7月4日主力资金净买入735.43万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449640401","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449640401?lang=zh_cn&edition=full","pubTime":"2024-07-05 09:13","pubTimestamp":1720141989,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月4日收盘,昊帆生物报收于40.93元,上涨1.31%,换手率8.41%,成交量2.08万手,成交额8293.25万元。近5日资金流向一览见下表:昊帆生物融资融券信息显示,融资方面,当日融资买入490.22万元,融资偿还487.78万元,融资净买入2.44万元。昊帆生物主营业务:多肽合成试剂、通用型分子砌块及蛋白质试剂等产品的研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500012498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2448424984","title":"昊帆生物:7月4日高管徐杰、陆雪根、吕敏杰、董胜军增持股份合计2.54万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448424984","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448424984?lang=zh_cn&edition=full","pubTime":"2024-07-04 20:01","pubTimestamp":1720094475,"startTime":"0","endTime":"0","summary":"证券之星消息,根据7月4日市场公开信息、上市公司公告及交易所披露数据整理,昊帆生物最新董监高及相关人员股份变动情况:2024年7月4日公司董事,副总经理徐杰、董事,副总经理陆雪根、董事,副总经理吕敏杰、董事会秘书,副总经理董胜军共增持公司股份2.54万股,占公司总股本为0.0235%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070400039247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2448522446","title":"昊帆生物(301393.SZ)获多位董高合计增持2.54万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448522446","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448522446?lang=zh_cn&edition=full","pubTime":"2024-07-04 18:37","pubTimestamp":1720089453,"startTime":"0","endTime":"0","summary":"昊帆生物(301393.SZ)公告,公司部分董事、高级管理人员于2024年7月4日...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/astock/11.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/11.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2448445288","title":"昊帆生物最新公告:部分董事、高管拟1100万元-2200万元增持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2448445288","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448445288?lang=zh_cn&edition=full","pubTime":"2024-07-04 18:29","pubTimestamp":1720088992,"startTime":"0","endTime":"0","summary":"昊帆生物公告,公司部分董事、高级管理人员于2024年7月4日通过深圳证券交易所交易系统以集中竞价交易方式增持公司股份,合计增持2.54万股,成交总金额101.02万元。同时,上述人员计划自本次增持计划公告之日起6个月内继续增持公司股票,计划增持金额合计不低于1100万元且不超过2200万元。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070400035965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2445047240","title":"昊帆生物涨5.52%,开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2445047240","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445047240?lang=zh_cn&edition=full","pubTime":"2024-06-24 16:38","pubTimestamp":1719218330,"startTime":"0","endTime":"0","summary":"今日昊帆生物涨5.52%,收盘报47.99元。2024年4月11日,开源证券研究员余汝意,汪晋发布了对昊帆生物的研报《公司信息更新报告:业绩阶段性承压,自有产能逐步落地赋能中长期发展》,该研报对昊帆生物给出“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为开源证券的余汝意。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400021318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","161027"],"gpt_icon":0},{"id":"2445759776","title":"昊帆生物(301393.SZ)拟投建多肽合成试剂生产项目(一期) 投资总额10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445759776","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445759776?lang=zh_cn&edition=full","pubTime":"2024-06-21 20:20","pubTimestamp":1718972446,"startTime":"0","endTime":"0","summary":"智通财经APP讯,昊帆生物 发布公告,公司拟在江苏省淮安市投资设立全资子公司并建设“多肽合成试剂生产项目(一期)”。全资子公司名称拟定为“淮安昊帆生物医药有限公司”,注册资本为1亿元,股权结构为苏州昊帆生物股份有限公司100%持股,并由该子公司具体实施建设一期项目,搭建多肽合成试剂及中试车间,预计投资总额为10亿元,建设用地约220亩。本次投资的目的是进一步解决公司产能瓶颈,更好地满足下游客户需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1138921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2445759471","title":"昊帆生物(301393.SZ)拟推2024年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2445759471","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445759471?lang=zh_cn&edition=full","pubTime":"2024-06-21 20:17","pubTimestamp":1718972270,"startTime":"0","endTime":"0","summary":"智通财经APP讯,昊帆生物(301393.SZ)发布2024年限制性股票激励计划(草案),拟向激励对象授予的限制性股票总量为89.50万股,占本激励计划草案公告时公司股本总额的0.83%。其中,首次授予限制性股票71.60万股,预留17.90万股。首次授予部分限制性股票的授予价格为22.30元/股。预留部分限制性股票授予价格与首次授予部分限制性股票的授予价格相同。此次激励计划首次授予的激励对象总人数为125人,激励计划有效期自限制性股票首次授予之日起至激励对象获授的限制性股票全部归属或作废失效之日止,最长不超过60个月。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1138913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301393","BK0229"],"gpt_icon":0},{"id":"2445756173","title":"昊帆生物最新公告:拟10亿元投建多肽合成试剂生产项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2445756173","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445756173?lang=zh_cn&edition=full","pubTime":"2024-06-21 19:49","pubTimestamp":1718970584,"startTime":"0","endTime":"0","summary":"昊帆生物公告,公司拟在江苏省淮安市投资设立全资子公司并建设“多肽合成试剂生产项目(一期)”。预计投资总额为10亿元,建设用地约220亩。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062100046492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","301393"],"gpt_icon":0},{"id":"2445274947","title":"昊帆生物(301393)6月20日主力资金净买入1642.22万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445274947","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445274947?lang=zh_cn&edition=full","pubTime":"2024-06-21 09:10","pubTimestamp":1718932251,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月20日收盘,昊帆生物报收于44.27元,上涨9.31%,换手率19.6%,成交量4.85万手,成交额2.18亿元。近5日资金流向一览见下表:昊帆生物融资融券信息显示,融资方面,当日融资买入969.18万元,融资偿还1345.98万元,融资净偿还376.8万元。昊帆生物主营业务:多肽合成试剂、通用型分子砌块及蛋白质试剂等产品的研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062100015395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301393","BK0229"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2023-07-12","address":"江苏省苏州市虎丘区高新区长亭路1号","stockEarnings":[{"period":"1week","weight":-0.0003},{"period":"1month","weight":-0.0259},{"period":"3month","weight":-0.1872},{"period":"6month","weight":-0.0665},{"period":"1year","weight":-0.5344},{"period":"ytd","weight":-0.3454}],"companyName":"苏州昊帆生物股份有限公司","boardCode":"AI0026","perCapita":"2867股","boardName":"化学原料和化学制品制造业","registeredCapital":"10800万元","compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0282},{"period":"3month","weight":-0.0871},{"period":"6month","weight":0.0047},{"period":"1year","weight":-0.0899},{"period":"ytd","weight":-0.0321}],"survey":" 苏州昊帆生物股份有限公司主营业务为多肽合成试剂的研发、生产与销售。主要产品包括缩合试剂、保护试剂、手性消旋抑制试剂、蛋白质交联剂、蛋白质还原剂、通用型分子砌块、脂质体与脂质纳米粒药用试剂等。公司可为下游客户提供近150种结构新颖、质量优异的多肽合成试剂产品,是全球为数不多的能够提供全系列多肽合成试剂研发与产业化的公司之一,并在HATU、HBTU、TBTU、PyBOP等多个合成工艺更为先进、产品附加值更高、竞争壁垒更高的磷正离子型和脲正离子型产品领域处于市场主导地位。","serverTime":1723925890483,"listedPrice":67.68,"stockholders":"12434人(较上一季度减少28.83%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昊帆生物(301393)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昊帆生物(301393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昊帆生物,301393,昊帆生物股票,昊帆生物股票老虎,昊帆生物股票老虎国际,昊帆生物行情,昊帆生物股票行情,昊帆生物股价,昊帆生物股市,昊帆生物股票价格,昊帆生物股票交易,昊帆生物股票购买,昊帆生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昊帆生物(301393)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昊帆生物(301393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}